ClinicalTrials.gg
Not yet recruitingNCT07258862KTBIOUpdated Dec 2, 2025

Analysis of Microbial Biofilms in Peripheral Venous Catheters and Their Implication in Infectious Risk

An observational study in Catheter-Related Infections, sponsored by Hôpital NOVO. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Hôpital NOVO · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Catheter-Related Infections with a site in France — 4 open to participants now, 4 under way, none of them phase 3. Catheter-Related Infections · France.

Started
2026
with 3 others
Observational
6 of 16
2 open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Hôpital NOVO

Among the 16 studies in Catheter-Related Infections with a site in France, this one is one of 4 that started in 2026, is one of 6 observational ones, and was the 14th registered.

Catheter-Related Infections

113 studies on the registry are indexed under Catheter-Related Infections; 19 are open to participants now.

Browse Catheter-Related Infections studies →

Open to participants now

4 of the 16 studies in Catheter-Related Infections with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 10 Catheter-Related Infections studies recruiting now, 9 (90%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Catheter-Related Infections with a site in France, or all of them as a file.
02

Study summary

Peripheral venous catheters (PVCs) are the most commonly used intravascular medical devices in healthcare establishments. Although essential in patient care, PVCs represent a significant risk factor for nosocomial infections, as shown by the results of the national prevalence survey. While the main pathophysiological mechanisms are known, the specific factors driving the transition from simple colonization to infection remain unclear. This project aims to identify the major factors involved in the occurrence of bacterial infections related to the colonization of peripheral venous catheters.

Read the detailed description

Peripheral venous catheters (PVCs) are the most commonly used intravascular medical devices in healthcare establishments. In the 2022 national survey on the prevalence of nosocomial infections (NI), out of 151676 patients included, 22.45% had a peripheral venous catheter. Moreover, patients exposed to a PVC are 3 times more likely to suffer a nosocomial infection. Between 2019 and 2023, at national level, there was a significant increase in the proportion of PVC-related bloodstream infection. The pathophysiological mechanisms of catheter-related infections are mainly linked to contamination via the endoluminal route, through manipulations of connectors during perfusion connections, or via the extraluminal route, which is more likely to be associated with faulty catheter placement practices. Finally, even in patients with no clinical signs of infection, culture-negative PVCs show intra- and extra-luminal colonization.

This underscores our lack of understanding of the mechanisms that can lead from simple colonization of the equipment to localized catheter infection or even bacteraemia.

The main objective of this project is to identify the major factors involved in the occurrence of bacterial infections related to the colonization of peripheral venous catheters.

To investigate these mechanisms, the study will focus on the collection of PVCs after clinical removal, followed by molecular and super-resolution microscopy analyses. Catheters either removed by the care team, because they are no longer clinically relevant or for medical reasons, will be collected under aseptic conditions.

03

Conditions studied

  • Catheter-Related Infections

Keywords

  • Vascular Access Devices
  • Peripheral Venous Catheter
  • Catheter-Related Infections
  • Biofilms
  • Molecular Biology
  • Next-Generation Sequencing
  • Scanning Electron Microscopy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient hospitalized in a care unit of the NOVO hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient hospitalized in a care unit of the NOVO hospital (Pontoise site)
  • Major patient for whom a peripheral venous catheter has been in place for at least 2 days and at most 7 days, with or without signs of inflammation

Exclusion criteria

Exclusion Criteria:

  • Antibiotic treatment by any route
  • Patient with viral hepatitis, or (HIV) or suspected epidemic and biological risk (EBR)
  • Patient unable to understand and give non-opposition to study participation
  • Patient under guardianship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Inflammatory catheters

    Catheter removed because of infection at insertion site

    Diagnostic Test: Inflammatory catheters: catheter removed because of infection at insertion site

  • Non-inflammatory catheters

    catheter removed because it is no longer relevant to keep it in place

    Device: Non-inflammatory catheters: catheter removed because it is no longer relevant to keep it in place

Interventions

  • Diagnostic testInflammatory catheters: catheter removed because of infection at insertion site

    Verification of inclusion and non-inclusion criteria (at least 2 days and at most 7 days, with or without signs of inflammation). The doctor or a qualified nurse orally informs the patient when catheter removal is planned. The information and non-opposition note are given to the patient, and the information procedure is recorded in the medical record. The catheter is removed and collected under aseptic conditions by the nurses in the various departments, in a dry sterile tube. The tube is then labelled and stored at a maximum of 4°C. The catheter is sent to the hospital's biology laboratory before being collected by the approved carrier for delivery to the ERRMECe laboratory from CYU. All tests are performed in the ERRMECe laboratory. Collected catheters are subsequently analysed to assess the bacterial diversity of biofilms using molecular biology techniques and Next-Generation Sequencing (NGS), in parallel with biofilm structural analysis microscopy using a Scanning Electron Microsc

  • DeviceNon-inflammatory catheters: catheter removed because it is no longer relevant to keep it in place

    Verification of inclusion and non-inclusion criteria (at least 2 days and at most 7 days, with or without signs of inflammation). The doctor or a qualified nurse orally informs the patient when catheter removal is planned. The information and non-opposition note are given to the patient, and the information procedure is recorded in the medical record. The catheter is removed and collected under aseptic conditions by the nurses in the various departments, in a dry sterile tube. The tube is then labelled and stored at a maximum of 4°C. The catheter is sent to the hospital's biology laboratory before being collected by the approved carrier for delivery to the ERRMECe laboratory from CYU. All tests are performed in the ERRMECe laboratory. Collected catheters are subsequently analysed to assess the bacterial diversity of biofilms using molecular biology techniques and Next-Generation Sequencing (NGS), in parallel with biofilm structural analysis microscopy using a Scanning Electron Microsc

06

What researchers measure

Primary outcomes

  1. Bacterial diversity of biofilms in PVCs according to inflammatory symptoms

    Relative abundance of bacteria within biofilms present in CVPs as identified by NGS, according to inflammatory symptoms.

    Time frame: 15 months

Secondary outcomes

  1. Biofilms structural morphology in PVCs

    Qualitative imaging of microbial biofilms in PVCs using Scanning Electron Microscopy

    Time frame: 15 months

  2. Bacterial diversity of biofilms in PVCs according to type of substances administered through the vascular route

    Relative abundance of bacteria within biofilms present in PVCs as identified by NGS, according to the type of substances received by patients through the vascular route

    Time frame: 15 months

  3. Bacterial diversity of biofilms in PVCs according to catheter dwell time

    Relative abundance of bacteria within biofilms present in CVPs as identified by NGS, according to catheter dwell time.

    Time frame: 15 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Mar 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 2, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Mar 28, 2027
CompletionEst.
Mar 28, 2027
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07258862
Lead sponsor
Hôpital NOVO
Collaborators
Université de Cergy Pontoise
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Mar 28, 2027 (estimated)
Completion
Mar 28, 2027 (estimated)
Last update
Dec 2, 2025

Study contacts

Maryline DELATTRE
Contact
maryline.delattre@ght-novo.fr
+33130755031
Marylise ADECHIAN
Contact
marylise.adechian@ght-novo.fr
+33130755069
LECURU Marion, Doctor
principal investigator · Hôpital NOVO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion